Product Description
Mechanisms of Action: PPAR-d Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Type 2 Diabetes|Dyslipidemia|Metabolic Syndrome X|Overweight|Hyperglycemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2005-001558-26 | P2 |
Completed |
Overweight |
2007-06-25 |
|
ADG20001 | P2 |
Completed |
Type 2 Diabetes |
2007-04-01 |
|
ADG106149 | P2 |
Terminated |
Type 2 Diabetes |
2006-11-01 |
|
2006-001275-38 | P2 |
Terminated |
Hyperglycemia|Type 2 Diabetes |
2006-10-20 |